Immunic Presents Positive Phase 2 Data for Vidofludimus Calcium in Progressive MS
IMUX has more than doubled off its 52-week low of $5.062.
Summary
Immunic, Inc. announced positive additional data from its Phase 2 CALLIPER trial for vidofludimus calcium in progressive multiple sclerosis, highlighting a favorable safety profile and a novel statistical analysis showing both disability improvement and slowing of progression.
Key Events · Product Development and Regulatory · IMUX
-
Positive Phase 2 CALLIPER Data
Additional data from the Phase 2 CALLIPER trial for vidofludimus calcium (IMU-838) in progressive multiple sclerosis (PMS) were presented at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
-
Novel Disability Assessment
A late-breaking poster introduced a 'Novel Unified Statistical Analyses for Confirmed Disability Changes (CDC)' which integrates both confirmed disability worsening and improvement, consistently favoring vidofludimus calcium over placebo.
-
Favorable Safety and Tolerability
The data showed a comparable overall adverse events profile between vidofludimus calcium and placebo, reinforcing its favorable safety and tolerability.
-
Patient-Reported Outcomes
Patient-reported outcomes indicated no negative impact on mood and numerically favored vidofludimus calcium for treatment effectiveness.
Analysis · IMUX · Life Sciences
This 8-K reports the presentation of new, positive Phase 2 clinical data for Immunic's lead asset, vidofludimus calcium, in progressive multiple sclerosis. The data reinforces the drug's potential by demonstrating a favorable safety and tolerability profile, and introduces a novel statistical approach that shows both confirmed disability worsening and improvement, consistently favoring the drug over placebo. This strengthens the development path for vidofludimus calcium, which is already in Phase 3 for relapsing MS, and provides further confidence in its neuroprotective and anti-inflammatory mechanisms.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.7M. The 52-week trading range was $5.06 to $15.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.